| Literature DB >> 34930484 |
A I Burov1, T A Abramov2, N S Kostritca3, D S Korotkov2, G V Danilov2, Y V Strunina2, I A Savin2.
Abstract
BACKGROUND: For patients with primary brain injury, septic shock is especially dangerous due to the possibility of secondary cerebral damage. The key factor of sepsis-associated brain injury is inflammatory mediators, pathogen and damage-associated molecular patterns (PAMPs, DAMPs) release. Theoretically, blood purification may be beneficial for patients with primary brain injury due to its possibility for fast removal of inflammatory mediators. CASEEntities:
Keywords: Blood purification; Continuous renal replacement therapy; Hemoadsorption; High adsorption capacity membrane; Inflammatory mediators adsorber; Septic shock
Mesh:
Substances:
Year: 2021 PMID: 34930484 PMCID: PMC8691076 DOI: 10.1186/s40001-021-00614-7
Source DB: PubMed Journal: Eur J Med Res ISSN: 0949-2321 Impact factor: 2.175
Patient characteristics, major medical history, antibiotic therapy, scoring pre- and post-treatment
| Case no. | Name | Sex | Age | Major pathology | Source of infection | Pathogen | Antibiotics | Time before CBP hours | Initial SOFA score | Initial GCS | Initial FOUR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | S | F | 71 | Brain tumor removal | Urinary tract infection | Not determined | Meropenem, linezolid, ciprofloxacin | 10 | 12 | 10 | 11 |
| 2 | G | F | 82 | Aneurysm clipping after SAH | Pneumonia | Meropenem, linezolid, fluconazole, polymyxin E | 20 | 12 | 6 | 8 | |
| 3 | Ch | M | 55 | Brain trauma | Bloodstream infection | Meropenem, tigecycline, polymyxin E | 10 | 11 | 6 | 8 | |
| 4 | P | M | 29 | Aneurysm clipping after SAH | Bloodstream infection | Meropenem, linezolid, fluconazole, polymyxin E | 6 | 16 | 4 | 5 | |
| 5 | K | M | 56 | Aneurysm clipping after SAH | Bloodstream infection | Meropenem, linezolid, polymyxin E | 20 | 16 | 4 | 2 | |
| 6 | M | M | 68 | Brain tumor removal, PE, post-CPR | Pneumonia | MSSA | Meropenem, linezolid | 6 | 18 | 10 | 13 |
Patient clinical parameters, scoring pre- and post-treatment
| Name | NE | NE | NE | NE | Lac | Lac | Lac | Lac | SOFA score before CBP | SOFA score | SOFA | SOFA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | 0.77 | 0.09 | 0 | 0 | 4.40 | 2.2 | 4.7 | 4.7 | 12 | 8 | 6 | 8 |
| G | 1 | 0 | 0 | 0 | 2 | 1.8 | 2.9 | 1.8 | 12 | 4 | 5 | 4 |
| Ch | 0.18 | 0.23 | 0.17 | 0.16 | 2.1 | 1.9 | 1.3 | 0.7 | 11 | 8 | 9 | 9 |
| P | 2.13 | 1.64 | 1.8 | 3.6 | 9.8 | 7.3 | 7.7 | 5.8 | 16 | 15 | 15 | 18 |
| K | 0.71 | 0.15 | 0.15 | 1 | 2 | 1.1 | 1.2 | 1.5 | 16 | 14 | 15 | 15 |
| M | 1.68 | 2.24 | – | – | 9.6 | 7.9 | – | – | 18 | 17 | – | – |
Inflammatory mediator’s levels pre- and post-treatment
| Name | PCT | PCT | PCT | PCT | Cytokines | Cytokines | Cytokines | CRP | CRP | CRP | CRP | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL-6 | IL-10 | IL-6 | IL-10 | IL-6 | IL-10 | |||||||||
| S | > 200 | > 200 | 81.74 | 86.62 | 3797 | 585 | 464 | 31 | 85 | 21.1 | 34.7 | 23.7 | 35.4 | 28.2 |
| G | 18.13 | 4.15 | 4.46 | 4.43 | 194 | 9,5 | 34 | 5.0 | 76 | 5.7 | 71.6 | 48.6 | 57.2 | 48.8 |
| Ch | > 200 | 46.72 | 34.59 | 22.52 | 56 | < 5.0 | 34 | < 5.0 | 24 | < 5.0 | 182 | 181.5 | 102.2 | 69.8 |
| P | 139.53 | 57.65 | 66,53 | 78.29 | 32,280 | 1030 | 9142 | 80.6 | 6352 | 104 | 215.8 | 250 | 254.4 | 298.1 |
| K | 56 | 37.8 | 32 | 29.34 | 141 | 71.8 | 19.46 | 19.3 | 20.98 | 9.8 | 257.3 | 167.2 | 131.8 | 68 |
| M | 5.32 | 1.79 | 1.65 | 1.43 | 1598 | 133 | 592 | 50.1 | 344.6 | 14.8 | 95.1 | 129.7 | – | – |
Patient scoring pre- and post-treatment and patient outcome
| Name | Initial GCS | GCS | GCS | Initial | FOUR | FOUR | CRRT days | Shock reversal | 7-day mortality | 28-day mortality | Hospital mortality |
|---|---|---|---|---|---|---|---|---|---|---|---|
| S | 10 | 10 | 11 | 11 | 11 | 13 | 0 | Yes | No | No | No |
| G | 6 | 6 | 9 | 8 | 8 | 10 | 0 | Yes | No | Yes | Yes |
| Ch | 6 | 6 | 6 | 8 | 8 | 8 | 1 | Yes | No | No | No |
| P | 4 | 4 | 3 | 5 | 5 | 0 | 2 | No | Yes | Yes | Yes |
| K | 4 | 4 | 3 | 2 | 2 | 0 | 2 | Yes | Yes | Yes | Yes |
| M | 10 | 10 | – | 13 | 13 | – | 0 | No | Yes | Yes | Yes |
Fig. 1NE dose dynamics (µg/kg/min)
Fig. 2Lactate level dynamics (mmol/l). *p < 0.05
Fig. 3SOFA score dynamics. *p < 0.05
Fig. 4PCT level dynamics (ng/ml). *p < 0.05
Fig. 5IL-6 level dynamics (pg/ml) *p < 0.05
Fig. 6CRP level dynamics (mg/l)